UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2022~~2023


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES


An Illinois Corporation			I.R.S. Employer Identification No.
			36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer x			Accelerated Filer o

Non-Accelerated Filer o			Smaller reporting company o

			Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of September 30, ~~2022,~~2023, Abbott Laboratories had ~~1,743,573,777~~1,736,058,536 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)


		Three Months Ended				Nine Months Ended					Three Months Ended				Nine Months Ended
		September 30				September 30					September 30				September 30
		2022		2021		2022		2021			2023		2022		2023		2022
Net sales	Net sales	$	10,410	$	10,928	$	33,562	$	31,607	Net sales	$	10,143	$	10,410	$	29,868	$	33,562

Cost of products sold, excluding amortization of intangible assets	Cost of products sold, excluding amortization of intangible assets	4,629		4,423		14,549		13,771		Cost of products sold, excluding amortization of intangible assets	4,605		4,629		13,419		14,549
Amortization of intangible assets	Amortization of intangible assets	498		520		1,517		1,533		Amortization of intangible assets	496		498		1,485		1,517
Research and development	Research and development	782		672		2,163		1,980		Research and development	672		782		2,041		2,163
Selling, general and administrative	Selling, general and administrative	2,731		2,767		8,275		8,276		Selling, general and administrative	2,723		2,731		8,225		8,275
Total operating cost and expenses	Total operating cost and expenses	8,640		8,382		26,504		25,560		Total operating cost and expenses	8,496		8,640		25,170		26,504

Operating earnings	Operating earnings	1,770		2,546		7,058		6,047		Operating earnings	1,647		1,770		4,698		7,058

Interest expense	Interest expense	141		133		404		402		Interest expense	166		141		478		404
Interest (income)	Interest (income)	(55)		(10)		(95)		(32)		Interest (income)	(97)		(55)		(296)		(95)
Net foreign exchange (gain) loss	Net foreign exchange (gain) loss	19		4		16		7		Net foreign exchange (gain) loss	(10)		19		17		16
Other (income) expense, net	Other (income) expense, net	(93)		(74)		(253)		(214)		Other (income) expense, net	(83)		(93)		(370)		(253)
Earnings before taxes	Earnings before taxes	1,758		2,493		6,986		5,884		Earnings before taxes	1,671		1,758		4,869		6,986
Taxes on earnings	Taxes on earnings	323		393		1,086		802		Taxes on earnings	235		323		740		1,086
Net Earnings	Net Earnings	$	1,435	$	2,100	$	5,900	$	5,082	Net Earnings	$	1,436	$	1,435	$	4,129	$	5,900

Basic Earnings Per Common Share	Basic Earnings Per Common Share	$	0.82	$	1.18	$	3.35	$	2.85	Basic Earnings Per Common Share	$	0.82	$	0.82	$	2.36	$	3.35

Diluted Earnings Per Common Share	Diluted Earnings Per Common Share	$	0.81	$	1.17	$	3.32	$	2.83	Diluted Earnings Per Common Share	$	0.82	$	0.81	$	2.35	$	3.32

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,752,968		1,774,516		1,756,209		1,776,870		Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,738,700		1,752,968		1,740,255		1,756,209
Dilutive Common Stock Options	Dilutive Common Stock Options	10,685		14,483		11,638		14,407		Dilutive Common Stock Options	9,589		10,685		9,819		11,638
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,763,653		1,788,999		1,767,847		1,791,277		Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,748,289		1,763,653		1,750,074		1,767,847

Outstanding Common Stock Options Having No Dilutive Effect	Outstanding Common Stock Options Having No Dilutive Effect	5,445		2,740		2,655		2,694		Outstanding Common Stock Options Having No Dilutive Effect	7,334		5,445		5,474		2,655

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)


		Three Months Ended				Nine Months Ended					Three Months Ended				Nine Months Ended
		September 30				September 30					September 30				September 30
		2022		2021		2022		2021			2023		2022		2023		2022
Net Earnings	Net Earnings	$	1,435	$	2,100	$	5,900	$	5,082	Net Earnings	$	1,436	$	1,435	$	4,129	$	5,900
Foreign currency translation gain (loss) adjustments	Foreign currency translation gain (loss) adjustments	(1,008)		(391)		(1,429)		(762)		Foreign currency translation gain (loss) adjustments	(480)		(1,008)		(393)		(1,429)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021		56		78		172		211
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021		213		139		186		257
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(1) and $(4) in 2023 and $11 and $36 in 2022										Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $(1) and $(4) in 2023 and $11 and $36 in 2022	(9)		56		(13)		172
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 and $(24) in 2023 and $50 and $96 in 2022										Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $30 and $(24) in 2023 and $50 and $96 in 2022	80		213		(23)		186
Other comprehensive income (loss)	Other comprehensive income (loss)	(739)		(174)		(1,071)		(294)		Other comprehensive income (loss)	(409)		(739)		(429)		(1,071)
Comprehensive Income	Comprehensive Income	$	696	$	1,926	$	4,829	$	4,788	Comprehensive Income	$	1,027	$	696	$	3,700	$	4,829


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:	Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:					Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	Cumulative foreign currency translation (loss) adjustments	$	(7,268)	$	(5,839)	Cumulative foreign currency translation (loss) adjustments	$	(7,126)	$	(6,733)
Net actuarial (losses) and prior service (costs) and credits	Net actuarial (losses) and prior service (costs) and credits	(2,498)		(2,670)		Net actuarial (losses) and prior service (costs) and credits	(1,506)		(1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other	Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other	321		135		Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other	152		175
Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss)	$	(9,445)	$	(8,374)	Accumulated other comprehensive income (loss)	$	(8,480)	$	(8,051)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)


		September 30, 2022		December 31, 2021			September 30, 2023		December 31, 2022
Assets	Assets					Assets
Current Assets:	Current Assets:					Current Assets:
Cash and cash equivalents	Cash and cash equivalents	$	9,594	$	9,799	Cash and cash equivalents	$	6,709	$	9,882
Short-term investments	Short-term investments	313		450		Short-term investments	338		288
Trade receivables, less allowances of $520 in 2022 and $519 in 2021		6,408		6,487
Trade receivables, less allowances of $472 in 2023 and $500 in 2022						Trade receivables, less allowances of $472 in 2023 and $500 in 2022	6,499		6,218
Inventories:	Inventories:					Inventories:
Finished products	Finished products	3,407		3,081		Finished products	3,847		3,805
Work in process	Work in process	726		694		Work in process	888		680
Materials	Materials	1,601		1,382		Materials	1,915		1,688
Total inventories	Total inventories	5,734		5,157		Total inventories	6,650		6,173
Prepaid expenses and other receivables	Prepaid expenses and other receivables	2,796		2,346		Prepaid expenses and other receivables	2,468		2,663
Total Current Assets	Total Current Assets	24,845		24,239		Total Current Assets	22,664		25,224
Investments	Investments	764		816		Investments	788		766
Property and equipment, at cost	Property and equipment, at cost	19,306		19,364		Property and equipment, at cost	21,111		20,212
Less: accumulated depreciation and amortization	Less: accumulated depreciation and amortization	10,617		10,405		Less: accumulated depreciation and amortization	11,559		11,050
Net property and equipment	Net property and equipment	8,689		8,959		Net property and equipment	9,552		9,162
Intangible assets, net of amortization	Intangible assets, net of amortization	10,850		12,739		Intangible assets, net of amortization	9,282		10,454
Goodwill	Goodwill	22,284		23,231		Goodwill	23,277		22,799
Deferred income taxes and other assets	Deferred income taxes and other assets	5,369		5,212		Deferred income taxes and other assets	6,527		6,033
		$	72,801	$	75,196		$	72,090	$	74,438
Liabilities and Shareholders’ Investment	Liabilities and Shareholders’ Investment					Liabilities and Shareholders’ Investment
Current Liabilities:	Current Liabilities:					Current Liabilities:
Trade accounts payable	Trade accounts payable	$	4,133	$	4,408	Trade accounts payable	$	3,961	$	4,607
Salaries, wages and commissions	Salaries, wages and commissions	1,426		1,625		Salaries, wages and commissions	1,479		1,556
Other accrued liabilities	Other accrued liabilities	5,475		5,181		Other accrued liabilities	5,347		5,845
Dividends payable	Dividends payable	820		831		Dividends payable	886		887
Income taxes payable	Income taxes payable	394		306		Income taxes payable	318		343
Current portion of long-term debt	Current portion of long-term debt	1,117		754		Current portion of long-term debt	1,051		2,251
Total Current Liabilities	Total Current Liabilities	13,365		13,105		Total Current Liabilities	13,042		15,489
Long-term debt	Long-term debt	15,297		17,296		Long-term debt	14,477		14,522
Post-employment obligations, deferred income taxes and other long-term liabilities	Post-employment obligations, deferred income taxes and other long-term liabilities	8,255		8,771		Post-employment obligations, deferred income taxes and other long-term liabilities	6,877		7,522
Commitments and Contingencies	Commitments and Contingencies					Commitments and Contingencies
Shareholders’ Investment:	Shareholders’ Investment:					Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—		—		Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—		—
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421		24,560		24,470
Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228		(14,555)		(11,822)
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,305,154; 2022: 1,986,519,278						Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,987,305,154; 2022: 1,986,519,278	24,727		24,709
Common shares held in treasury, at cost — Shares: 2023: 251,246,618; 2022: 248,724,257						Common shares held in treasury, at cost — Shares: 2023: 251,246,618; 2022: 248,724,257	(15,686)		(15,229)
Earnings employed in the business	Earnings employed in the business	35,115		31,528		Earnings employed in the business	36,920		35,257
Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss)	(9,445)		(8,374)		Accumulated other comprehensive income (loss)	(8,480)		(8,051)
Total Abbott Shareholders’ Investment	Total Abbott Shareholders’ Investment	35,675		35,802		Total Abbott Shareholders’ Investment	37,481		36,686
Noncontrolling Interests in Subsidiaries	Noncontrolling Interests in Subsidiaries	209		222		Noncontrolling Interests in Subsidiaries	213		219
Total Shareholders’ Investment	Total Shareholders’ Investment	35,884		36,024		Total Shareholders’ Investment	37,694		36,905
		$	72,801	$	75,196		$	72,090	$	74,438

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

~~Abbott Laboratories and Subsidiaries~~

~~Condensed Consolidated Statement of Shareholders’ Investment~~

~~(Unaudited)~~

~~(in millions except shares and per share data)~~

Three Months Ended September 30
2022 2021
Common Shares:
Balance at June 30
Shares: 2022: 1,985,676,735; 2021: 1,982,553,488 $ 24,429 $ 24,153
Issued under incentive stock programs
Shares: 2022: 242,705; 2021: 550,366 12 26
Share-based compensation 123 113
Issuance of restricted stock awards (4) (7)
Balance at September 30
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854 $ 24,560 $ 24,285
Common Shares Held in Treasury:
Balance at June 30
Shares: 2022: 234,456,992; 2021: 209,736,139 $ (13,720) $ (10,340)
Issued under incentive stock programs
Shares: 2022: 528,436; 2021: 545,860 31 26
Purchased
Shares: 2022: 8,417,107; 2021: 5,626,606 (866) (685)
Balance at September 30
Shares: 2022: 242,345,663; 2021: 214,816,885 $ (14,555) $ (10,999)
Earnings Employed in the Business:
Balance at June 30 $ 34,487 $ 29,053
Net earnings 1,435 2,100
Cash dividends declared on common shares (per share — 2022: $0.47; 2021: $0.45) (822) (799)
Effect of common and treasury share transactions 15 22
Balance at September 30 $ 35,115 $ 30,376
Accumulated Other Comprehensive Income (Loss):
Balance at June 30 $ (8,706) $ (9,066)
Other comprehensive income (loss) (739) (174)
Balance at September 30 $ (9,445) $ (9,240)
Noncontrolling Interests in Subsidiaries:
Balance at June 30 $ 226 $ 229
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases (17) (13)
Balance at September 30 $ 209 $ 216

~~The accompanying notes to condensed consolidated financial statements are an integral part of this statement.~~

~~Table of Contents~~

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)


		Nine Months Ended September 30					Three Months Ended September 30
		2022		2021			2023		2022
Common Shares:	Common Shares:					Common Shares:
Balance at January 1
Shares: 2022: 1,985,273,421; 2021: 1,981,156,896		$	24,470	$	24,145
Balance at June 30						Balance at June 30
Shares: 2023: 1,987,181,491; 2022: 1,985,676,735						Shares: 2023: 1,987,181,491; 2022: 1,985,676,735	$	24,612	$	24,429
Issued under incentive stock programs	Issued under incentive stock programs					Issued under incentive stock programs
Shares: 2022: 646,019; 2021: 1,946,958		36		91
Shares: 2023: 123,663; 2022: 242,705						Shares: 2023: 123,663; 2022: 242,705	6		12
Share-based compensation	Share-based compensation	572		536		Share-based compensation	116		123
Issuance of restricted stock awards	Issuance of restricted stock awards	(518)		(487)		Issuance of restricted stock awards	(7)		(4)
Balance at September 30	Balance at September 30					Balance at September 30
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854		$	24,560	$	24,285
Shares: 2023: 1,987,305,154; 2022: 1,985,919,440						Shares: 2023: 1,987,305,154; 2022: 1,985,919,440	$	24,727	$	24,560

Common Shares Held in Treasury:	Common Shares Held in Treasury:					Common Shares Held in Treasury:
Balance at January 1
Shares: 2022: 221,191,228; 2021: 209,926,622		$	(11,822)	$	(10,042)
Balance at June 30						Balance at June 30
Shares: 2023: 251,823,511; 2022: 234,456,992						Shares: 2023: 251,823,511; 2022: 234,456,992	$	(15,722)	$	(13,720)
Issued under incentive stock programs	Issued under incentive stock programs					Issued under incentive stock programs
Shares: 2022: 4,808,575; 2021: 5,524,291		261		265
Shares: 2023: 579,159; 2022: 528,436						Shares: 2023: 579,159; 2022: 528,436	36		31
Purchased	Purchased					Purchased
Shares: 2022: 25,963,010; 2021: 10,414,554		(2,994)		(1,222)
Shares: 2023: 2,266; 2022: 8,417,107						Shares: 2023: 2,266; 2022: 8,417,107	—		(866)
Balance at September 30	Balance at September 30					Balance at September 30
Shares: 2022: 242,345,663; 2021: 214,816,885		$	(14,555)	$	(10,999)
Shares: 2023: 251,246,618; 2022: 242,345,663						Shares: 2023: 251,246,618; 2022: 242,345,663	$	(15,686)	$	(14,555)

Earnings Employed in the Business:	Earnings Employed in the Business:					Earnings Employed in the Business:
Balance at January 1		$	31,528	$	27,627
Balance at June 30						Balance at June 30	$	36,355	$	34,487
Net earnings	Net earnings	5,900		5,082		Net earnings	1,436		1,435
Cash dividends declared on common shares (per share — 2022: $1.41; 2021: $1.35)		(2,475)		(2,403)
Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47)						Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47)	(889)		(822)
Effect of common and treasury share transactions	Effect of common and treasury share transactions	162		70		Effect of common and treasury share transactions	18		15
Balance at September 30	Balance at September 30	$	35,115	$	30,376	Balance at September 30	$	36,920	$	35,115

Accumulated Other Comprehensive Income (Loss):	Accumulated Other Comprehensive Income (Loss):					Accumulated Other Comprehensive Income (Loss):
Balance at January 1		$	(8,374)	$	(8,946)
Balance at June 30						Balance at June 30	$	(8,071)	$	(8,706)
Other comprehensive income (loss)	Other comprehensive income (loss)	(1,071)		(294)		Other comprehensive income (loss)	(409)		(739)
Balance at September 30	Balance at September 30	$	(9,445)	$	(9,240)	Balance at September 30	$	(8,480)	$	(9,445)

Noncontrolling Interests in Subsidiaries:	Noncontrolling Interests in Subsidiaries:					Noncontrolling Interests in Subsidiaries:
Balance at January 1		$	222	$	219
Balance at June 30						Balance at June 30	$	230	$	226
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases	Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases	(13)		(3)		Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases	(17)		(17)
Balance at September 30	Balance at September 30	$	209	$	216	Balance at September 30	$	213	$	209

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)


	Nine Months Ended September 30
	2023		2022
Common Shares:
Balance at January 1
Shares: 2023: 1,986,519,278; 2022: 1,985,273,421	$	24,709	$	24,470
Issued under incentive stock programs
Shares: 2023: 785,876; 2022: 646,019	36		36
Share-based compensation	531		572
Issuance of restricted stock awards	(549)		(518)
Balance at September 30
Shares: 2023: 1,987,305,154; 2022: 1,985,919,440	$	24,727	$	24,560

Common Shares Held in Treasury:
Balance at January 1
Shares: 2023: 248,724,257; 2022: 221,191,228	$	(15,229)	$	(11,822)
Issued under incentive stock programs
Shares: 2023: 4,669,629; 2022: 4,808,575	288		261
Purchased
Shares: 2023: 7,191,990; 2022: 25,963,010	(745)		(2,994)
Balance at September 30
Shares: 2023: 251,246,618; 2022: 242,345,663	$	(15,686)	$	(14,555)

Earnings Employed in the Business:
Balance at January 1	$	35,257	$	31,528
Net earnings	4,129		5,900
Cash dividends declared on common shares (per share — 2023: $1.53; 2022: $1.41)	(2,668)		(2,475)
Effect of common and treasury share transactions	202		162
Balance at September 30	$	36,920	$	35,115

Accumulated Other Comprehensive Income (Loss):
Balance at January 1	$	(8,051)	$	(8,374)
Other comprehensive income (loss)	(429)		(1,071)
Balance at September 30	$	(8,480)	$	(9,445)

Noncontrolling Interests in Subsidiaries:
Balance at January 1	$	219	$	222
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases	(6)		(13)
Balance at September 30	$	213	$	209

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)


		Nine Months Ended September 30					Nine Months Ended September 30
		2022		2021			2023		2022
Cash Flow From (Used in) Operating Activities:	Cash Flow From (Used in) Operating Activities:					Cash Flow From (Used in) Operating Activities:
Net earnings	Net earnings	$	5,900	$	5,082	Net earnings	$	4,129	$	5,900
Adjustments to reconcile net earnings to net cash from operating activities —	Adjustments to reconcile net earnings to net cash from operating activities —					Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation	Depreciation	943		1,122		Depreciation	945		943
Amortization of intangible assets	Amortization of intangible assets	1,517		1,533		Amortization of intangible assets	1,485		1,517
Share-based compensation	Share-based compensation	570		534		Share-based compensation	530		570
Trade receivables	Trade receivables	(409)		(194)		Trade receivables	(424)		(409)
Inventories	Inventories	(1,224)		(471)		Inventories	(527)		(1,224)
Other, net	Other, net	(42)		(140)		Other, net	(1,915)		(42)
Net Cash From Operating Activities	Net Cash From Operating Activities	7,255		7,466		Net Cash From Operating Activities	4,223		7,255

Cash Flow From (Used in) Investing Activities:	Cash Flow From (Used in) Investing Activities:					Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	Acquisitions of property and equipment	(1,167)		(1,271)		Acquisitions of property and equipment	(1,447)		(1,167)
Acquisitions of businesses and technologies, net of cash acquired	Acquisitions of businesses and technologies, net of cash acquired	—		(187)		Acquisitions of businesses and technologies, net of cash acquired	(877)		—
Proceeds from business dispositions	Proceeds from business dispositions	48		134		Proceeds from business dispositions	40		48
Sales (purchases) of other investment securities, net	Sales (purchases) of other investment securities, net	(3)		(27)		Sales (purchases) of other investment securities, net	(45)		(3)
Other	Other	14		14		Other	20		14
Net Cash From (Used in) Investing Activities	Net Cash From (Used in) Investing Activities	(1,108)		(1,337)		Net Cash From (Used in) Investing Activities	(2,309)		(1,108)

Cash Flow From (Used in) Financing Activities:	Cash Flow From (Used in) Financing Activities:					Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other	Net borrowings (repayments) of short-term debt and other	37		(7)		Net borrowings (repayments) of short-term debt and other	(90)		37
Proceeds from issuance of long-term debt	Proceeds from issuance of long-term debt	7		—		Proceeds from issuance of long-term debt	1		7
Repayments of long-term debt	Repayments of long-term debt	(753)		(45)		Repayments of long-term debt	(1,447)		(753)
Purchases of common shares	Purchases of common shares	(3,110)		(1,325)		Purchases of common shares	(968)		(3,110)
Proceeds from stock options exercised	Proceeds from stock options exercised	126		173		Proceeds from stock options exercised	133		126
Dividends paid	Dividends paid	(2,486)		(2,404)		Dividends paid	(2,668)		(2,486)
Net Cash From (Used in) Financing Activities	Net Cash From (Used in) Financing Activities	(6,179)		(3,608)		Net Cash From (Used in) Financing Activities	(5,039)		(6,179)

Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(173)		(57)		Effect of exchange rate changes on cash and cash equivalents	(48)		(173)

Net Increase (Decrease) in Cash and Cash Equivalents	Net Increase (Decrease) in Cash and Cash Equivalents	(205)		2,464		Net Increase (Decrease) in Cash and Cash Equivalents	(3,173)		(205)
Cash and Cash Equivalents, Beginning of Year	Cash and Cash Equivalents, Beginning of Year	9,799		6,838		Cash and Cash Equivalents, Beginning of Year	9,882		9,799
Cash and Cash Equivalents, End of Period	Cash and Cash Equivalents, End of Period	$	9,594	$	9,302	Cash and Cash Equivalents, End of Period	$	6,709	$	9,594

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2023

(Unaudited)

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following tables provide detail by sales category:


		Three Months Ended September 30, 2022						Three Months Ended September 30, 2021							Three Months Ended September 30, 2023						Three Months Ended September 30, 2022
(in millions)	(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —	Established Pharmaceutical Products —													Established Pharmaceutical Products —
Key Emerging Markets	Key Emerging Markets	$	—	$	993	$	993	$	—	$	936	$	936	Key Emerging Markets	$	—	$	987	$	987	$	—	$	1,001	$	1,001
Other	Other	—		333		333		—		329		329		Other	—		381		381		—		325		325
Total	Total	—		1,326		1,326		—		1,265		1,265		Total	—		1,368		1,368		—		1,326		1,326
Nutritionals —	Nutritionals —													Nutritionals —
Pediatric Nutritionals	Pediatric Nutritionals	357		470		827		586		514		1,100		Pediatric Nutritionals	506		495		1,001		357		470		827
Adult Nutritionals	Adult Nutritionals	329		639		968		333		675		1,008		Adult Nutritionals	354		718		1,072		329		639		968
Total	Total	686		1,109		1,795		919		1,189		2,108		Total	860		1,213		2,073		686		1,109		1,795
Diagnostics —	Diagnostics —													Diagnostics —
Core Laboratory	Core Laboratory	281		938		1,219		291		1,001		1,292		Core Laboratory	317		997		1,314		281		938		1,219
Molecular	Molecular	65		118		183		162		183		345		Molecular	38		95		133		65		118		183
Point of Care	Point of Care	92		35		127		100		35		135		Point of Care	97		43		140		92		35		127
Rapid Diagnostics	Rapid Diagnostics	1,303		839		2,142		1,394		746		2,140		Rapid Diagnostics	561		301		862		1,273		839		2,112
Total	Total	1,741		1,930		3,671		1,947		1,965		3,912		Total	1,013		1,436		2,449		1,711		1,930		3,641
Medical Devices —	Medical Devices —													Medical Devices —
Rhythm Management	Rhythm Management	263		270		533		266		305		571		Rhythm Management	271		292		563		263		270		533
Electrophysiology	Electrophysiology	225		244		469		192		293		485		Electrophysiology	246		298		544		225		244		469
Heart Failure	Heart Failure	177		51		228		170		59		229		Heart Failure	217		67		284		207		51		258
Vascular	Vascular	213		393		606		219		425		644		Vascular	251		421		672		213		393		606
Structural Heart	Structural Heart	207		213		420		177		215		392		Structural Heart	223		264		487		207		213		420
Neuromodulation	Neuromodulation	156		36		192		149		41		190		Neuromodulation	188		39		227		156		36		192
Diabetes Care	Diabetes Care	423		744		1,167		323		798		1,121		Diabetes Care	544		928		1,472		423		744		1,167
Total	Total	1,664		1,951		3,615		1,496		2,136		3,632		Total	1,940		2,309		4,249		1,694		1,951		3,645

Other	Other	3		—		3		6		5		11		Other	4		—		4		3		—		3

Total	Total	$	4,094	$	6,316	$	10,410	$	4,368	$	6,560	$	10,928	Total	$	3,817	$	6,326	$	10,143	$	4,094	$	6,316	$	10,410

910

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 23 — Revenue (Continued)


		Nine Months Ended September 30, 2022						Nine Months Ended September 30, 2021							Nine Months Ended September 30, 2023						Nine Months Ended September 30, 2022
(in millions)	(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —	Established Pharmaceutical Products —													Established Pharmaceutical Products —
Key Emerging Markets	Key Emerging Markets	$	—	$	2,826	$	2,826	$	—	$	2,672	$	2,672	Key Emerging Markets	$	—	$	2,889	$	2,889	$	—	$	2,853	$	2,853
Other	Other	—		870		870		—		843		843		Other	—		955		955		—		843		843
Total	Total	—		3,696		3,696		—		3,515		3,515		Total	—		3,844		3,844		—		3,696		3,696
Nutritionals —	Nutritionals —													Nutritionals —
Pediatric Nutritionals	Pediatric Nutritionals	1,108		1,491		2,599		1,622		1,637		3,259		Pediatric Nutritionals	1,472		1,477		2,949		1,108		1,491		2,599
Adult Nutritionals	Adult Nutritionals	1,016		2,027		3,043		1,006		1,987		2,993		Adult Nutritionals	1,081		2,086		3,167		1,016		2,027		3,043
Total	Total	2,124		3,518		5,642		2,628		3,624		6,252		Total	2,553		3,563		6,116		2,124		3,518		5,642
Diagnostics —	Diagnostics —													Diagnostics —
Core Laboratory	Core Laboratory	836		2,788		3,624		845		2,935		3,780		Core Laboratory	917		2,872		3,789		836		2,788		3,624
Molecular	Molecular	308		507		815		431		651		1,082		Molecular	128		293		421		308		507		815
Point of Care	Point of Care	284		110		394		289		112		401		Point of Care	289		127		416		284		110		394
Rapid Diagnostics	Rapid Diagnostics	5,523		2,923		8,446		3,178		2,732		5,910		Rapid Diagnostics	1,975		853		2,828		5,436		2,923		8,359
Total	Total	6,951		6,328		13,279		4,743		6,430		11,173		Total	3,309		4,145		7,454		6,864		6,328		13,192
Medical Devices —	Medical Devices —													Medical Devices —
Rhythm Management	Rhythm Management	775		830		1,605		776		881		1,657		Rhythm Management	800		873		1,673		775		830		1,605
Electrophysiology	Electrophysiology	667		773		1,440		580		823		1,403		Electrophysiology	729		873		1,602		667		773		1,440
Heart Failure	Heart Failure	523		167		690		483		167		650		Heart Failure	661		199		860		610		167		777
Vascular	Vascular	650		1,228		1,878		684		1,292		1,976		Vascular	733		1,271		2,004		650		1,228		1,878
Structural Heart	Structural Heart	604		667		1,271		537		654		1,191		Structural Heart	652		794		1,446		604		667		1,271
Neuromodulation	Neuromodulation	456		112		568		460		124		584		Neuromodulation	528		122		650		456		112		568
Diabetes Care	Diabetes Care	1,165		2,320		3,485		865		2,292		3,157		Diabetes Care	1,528		2,681		4,209		1,165		2,320		3,485
Total	Total	4,840		6,097		10,937		4,385		6,233		10,618		Total	5,631		6,813		12,444		4,927		6,097		11,024

Other	Other	8		—		8		31		18		49		Other	10		—		10		8		—		8

Total	Total	$	13,923	$	19,639	$	33,562	$	11,787	$	19,820	$	31,607	Total	$	11,503	$	18,365	$	29,868	$	13,923	$	19,639	$	33,562

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.

Remaining Performance Obligations

As of September 30, ~~2022,~~2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately ~~$3.9~~$4.2 billion in the Diagnostics segment and approximately ~~$433~~$456 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 6059 percent of these remaining performance obligations over the next 24 months, approximately 1617 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in ~~Financial Accounting Standards Board (FASB)~~FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

1011

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 23 — Revenue (Continued)

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices ~~reportable~~ segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:


(in millions)
Contract Liabilities:
Balance at December 31, ~~2021~~2022	$	~~520~~500
Unearned revenue from cash received during the period	~~466~~346
Revenue recognized related to contract liability balance	~~(508)~~(292)
Balance at September 30, ~~2022~~2023	$	~~478~~554

Note 34 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September 30, 2023 and 2022 ~~and 2021~~ were ~~$1.429~~$1.431 billion and ~~$2.092~~$1.429 billion, respectively, and for the nine months ended September 30, 2023 and 2022 ~~and 2021~~ were ~~$5.876~~$4.113 billion and ~~$5.061~~$5.876 billion, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2023 includes $302 million of pension contributions and the payment of cash taxes of approximately $1.180 billion. The first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million. ~~The first nine months of 2021 includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million.~~

The following summarizes the activity for the first nine months of ~~2022~~2023 related to the allowance for doubtful accounts as of September 30, ~~2022:~~2023:


(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, ~~2021~~2022	$	~~313~~262
Provisions/charges to income	1022
Amounts charged off and other deductions	~~(49)~~(25)
Balance at September 30, ~~2022~~2023	$	~~274~~259

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

1112

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 34 — Supplemental Financial Information (Continued)

The components of long-term investments as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 are as follows:


(in millions)	(in millions)	September 30, 2022		December 31, 2021		(in millions)	September 30, 2023		December 31, 2022
Long-term Investments:	Long-term Investments:					Long-term Investments:
Equity securities	Equity securities	$	604	$	748	Equity securities	$	566	$	558
Other	Other	160		68		Other	222		208
Total	Total	$	764	$	816	Total	$	788	$	766

The ~~decrease~~increase in Abbott’s long-term investments as of September 30, ~~2022~~2023 versus the balance as of December 31, ~~2021~~2022 is primarily ~~relates~~due to investments acquired as part of a ~~decrease in the value of~~business acquisition and other additional investments, ~~held in a rabbi trust and~~partially offset by the impact of equity method investment ~~losses partially offset by an investment in long-term time deposits.~~losses.

Abbott’s equity securities as of September 30, ~~2022,~~2023 include ~~$285~~$291 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. ~~(St. Jude Medical)~~ business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of September 30, ~~2022~~2023 with a carrying value of ~~$228~~$175 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately ~~$83~~$87 million that do not have a readily determinable fair value.

In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s condensed consolidated financial statements.

Note 45 — Changes In Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:


		Three Months Ended September 30													Three Months Ended September 30
		Cumulative Foreign Currency Translation (Loss) Adjustments				Net Actuarial (Losses) and Prior Service (Costs) and Credits				Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other					Cumulative Foreign Currency Translation (Loss) Adjustments				Net Actuarial (Losses) and Prior Service (Costs) and Credits				Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other
(in millions)	(in millions)	2022		2021		2022		2021		2022		2021		(in millions)	2023		2022		2023		2022		2023		2022
Balance at June 30	Balance at June 30	$	(6,260)	$	(5,230)	$	(2,554)	$	(3,738)	$	108	$	(98)	Balance at June 30	$	(6,646)	$	(6,260)	$	(1,497)	$	(2,554)	$	72	$	108
Other comprehensive income (loss) before reclassifications	Other comprehensive income (loss) before reclassifications	(1,008)		(391)		15		16		278		70		Other comprehensive income (loss) before reclassifications	(497)		(1,008)		(9)		15		96		278
Amounts reclassified from accumulated other comprehensive income	Amounts reclassified from accumulated other comprehensive income	—		—		41		62		(65)		69		Amounts reclassified from accumulated other comprehensive income	17		—		—		41		(16)		(65)
Net current period comprehensive income (loss)	Net current period comprehensive income (loss)	(1,008)		(391)		56		78		213		139		Net current period comprehensive income (loss)	(480)		(1,008)		(9)		56		80		213
Balance at September 30	Balance at September 30	$	(7,268)	$	(5,621)	$	(2,498)	$	(3,660)	$	321	$	41	Balance at September 30	$	(7,126)	$	(7,268)	$	(1,506)	$	(2,498)	$	152	$	321

1213

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 45 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)


		Nine Months Ended September 30													Nine Months Ended September 30
		Cumulative Foreign Currency Translation (Loss) Adjustments				Net Actuarial (Losses) and Prior Service (Costs) and Credits				Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other					Cumulative Foreign Currency Translation (Loss) Adjustments				Net Actuarial (Losses) and Prior Service (Costs) and Credits				Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other
(in millions)	(in millions)	2022		2021		2022		2021		2022		2021		(in millions)	2023		2022		2023		2022		2023		2022
Balance at January 1	Balance at January 1	$	(5,839)	$	(4,859)	$	(2,670)	$	(3,871)	$	135	$	(216)	Balance at January 1	$	(6,733)	$	(5,839)	$	(1,493)	$	(2,670)	$	175	$	135
Other comprehensive income (loss) before reclassifications	Other comprehensive income (loss) before reclassifications	(1,429)		(762)		45		26		289		138		Other comprehensive income (loss) before reclassifications	(410)		(1,429)		(6)		45		134		289
Amounts reclassified from accumulated other comprehensive income	Amounts reclassified from accumulated other comprehensive income	—		—		127		185		(103)		119		Amounts reclassified from accumulated other comprehensive income	17		—		(7)		127		(157)		(103)
Net current period comprehensive income (loss)	Net current period comprehensive income (loss)	(1,429)		(762)		172		211		186		257		Net current period comprehensive income (loss)	(393)		(1,429)		(13)		172		(23)		186
Balance at September 30	Balance at September 30	$	(7,268)	$	(5,621)	$	(2,498)	$	(3,660)	$	321	$	41	Balance at September 30	$	(7,126)	$	(7,268)	$	(1,506)	$	(2,498)	$	152	$	321

Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 1113 for additional details.

Note 56 — Business Acquisitions

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management even more personal and precise. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Bigfoot since the date of acquisition are not material to Abbott's condensed consolidated financial statements.

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

The preliminary allocation of the purchase price of the CSI acquisition resulted in the recording of two non-deductible developed technology intangible assets of $305 million; non-deductible in-process research and development of $15 million, which will be accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately $384 million; net deferred tax assets of approximately $31 million and other net assets of approximately $116 million. The goodwill is identifiable to the Medical Devices reportable segment and is attributable to expected synergies from combining operations, as well as intangible assets that do not qualify for separate recognition. Allocation of the purchase price of the acquisition will be finalized when the valuation of assets and liabilities is completed. Revenues and earnings of CSI included in Abbott's consolidated financial statements since the acquisition date are not material to Abbott's consolidated revenue and earnings. If the acquisition of CSI had taken place as of the beginning of 2022, consolidated net sales and earnings would not have been significantly different from reported amounts.

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was ~~$22.3~~$23.3 billion at September 30, ~~2022~~2023 and ~~$23.2~~$22.8 billion at December 31, ~~2021. Foreign~~2022. Recent business acquisitions increased goodwill by approximately $590 million and foreign currency translation adjustments decreased goodwill by approximately ~~$946~~$112 million in the first nine months of ~~2022.~~2023. The amount of goodwill related to reportable segments at September 30, ~~2022~~2023 was $2.6 billion for the Established Pharmaceutical Products segment, ~~$286~~$285 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and ~~$15.9~~$16.8 billion for the Medical Devices segment. There ~~was~~were no ~~reduction~~reductions of goodwill relating to impairments in the first nine months of ~~2022.~~

The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September 30, 2022 and December 31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September 30, 2022 and December 31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and $1.6 billion in 2026.

Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $807 million as of September 30, 2022 and $919 million as of December 31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the Medical Devices business segment.

~~Note 6 — Restructuring Plans~~

On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2022~~

~~(Unaudited)~~

~~Note 6 — Restructuring Plans (Continued)~~

In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.

~~The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:~~

(in millions) Inventory-
Related
Charges Fixed Asset
Write-Downs Other Exit
Costs Total
Restructuring charges recorded in 2021 $ 248 $ 80 $ 113 $ 441
Payments — — (90) (90)
Other non-cash (248) (80) — (328)
Accrued balance at December 31, 2021 — — 23 23
Payments and other adjustments — — (10) (10)
Accrued balance at September 30, 2022 $ — $ — $ 13 $ 13

In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott’s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately $5 million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5 million was recorded in Selling, general and administrative expense.

~~The following summarizes the activity for these restructurings:~~


~~(in millions)~~
~~Restructuring charges recorded in 2021~~	$	68
~~Payments and other adjustments~~	~~(7)~~
~~Accrued balance at December 31, 2021~~	61
~~Restructuring charges recorded in 2022~~	12
~~Payments and other adjustments~~	~~(39)~~
~~Accrued balance at September 30, 2022~~	$	34

2023.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 7 — Goodwill and Intangible Assets (continued)

The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.5 billion and $27.2 billion as of September 30, 2023 and December 31, 2022, respectively. The gross amount of amortizable intangible assets increased by $305 million due to a recent business acquisition. Accumulated amortization was $19.0 billion and $17.6 billion as of September 30, 2023 and December 31, 2022, respectively. Foreign currency translation adjustments decreased intangible assets by $14 million in the first nine months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, $1.6 billion in 2026 and $1.3 billion in 2027.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were approximately $832 million as of September 30, 2023 and $807 million as of December 31, 2022. Recent business acquisitions increased IPR&D by $80 million. This increase was partially offset by $55 million of charges recorded on the Research and development line of the Condensed Consolidated Statement of Earnings for the impairment of certain indefinite-lived intangible assets related to the Medical Devices reportable segment.

Note 8 — Restructuring Plans

In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the nine months ended September 30, 2023, Abbott recorded employee related severance and other charges of approximately $102 million, of which approximately $31 million was recorded in Cost of products sold, approximately $16 million was recorded in Research and development, and approximately $55 million was recorded in Selling, general and administrative expenses. In addition, Abbott recognized fixed asset impairment charges of approximately $29 million related to these restructuring plans.

The following summarizes the activity related to these restructuring actions and the status of the related accruals as of September 30, 2023:


(in millions)	Total
Accrued balance at December 31, 2022	$	228
Restructuring charges in 2023	102
Payments and other adjustments	(181)
Accrued balance at September 30, 2023	$	149

Note 9 — Incentive Stock ~~Program~~Programs

In the first nine months of ~~2022,~~2023, Abbott granted ~~2,634,647~~1,986,671 stock options, ~~514,205~~463,856 restricted stock awards and ~~5,427,697~~4,927,476 restricted stock units under its incentive stock program. At September 30, ~~2022,~~2023, approximately 8774 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September 30, ~~2022~~2023 is as follows:


		Outstanding		Exercisable			Outstanding		Exercisable
Number of shares	Number of shares	29,048,449		23,310,464		Number of shares	29,342,041		24,718,236
Weighted average remaining life (years)	Weighted average remaining life (years)	5.4		4.6		Weighted average remaining life (years)	5.0		4.3
Weighted average exercise price	Weighted average exercise price	$	70.22	$	59.69	Weighted average exercise price	$	73.77	$	66.27
Aggregate intrinsic value (in millions)	Aggregate intrinsic value (in millions)	$	901	$	890	Aggregate intrinsic value (in millions)	$	825	$	825

The total unrecognized share-based compensation cost at September 30, ~~2022~~2023 amounted to approximately ~~$600~~$560 million which is expected to be recognized over the next three years.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2023

(Unaudited)

Note 810 — Debt and Lines of Credit

On September 27, 2023, Abbott repaid the €1.14 billion outstanding principal amount of its 0.875% Notes upon maturity. The repayment equated to approximately $1.2 billion. In September 2023, Abbott repaid approximately $197 million of debt assumed as part of a recent business acquisition. On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.

Note 911 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling ~~$7.9~~$7.3 billion at September 30, ~~2022~~2023 and ~~$8.6~~$7.7 billion at December 31, ~~2021,~~2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, ~~2022~~2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, Abbott held the gross notional amounts of ~~$10.3~~$14.2 billion and ~~$12.2~~$12.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately ~~$413~~$401 million and ~~$521~~$446 million as of September 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with a notional ~~values~~amount totaling approximately $2.9 billion at September 30, ~~2022~~2023 and December 31, ~~2021~~2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 911 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of September 30, ~~2022~~2023 and December 31, ~~2021:~~2022:


		Fair Value - Assets					Fair Value - Liabilities						Fair Value - Assets					Fair Value - Liabilities
(in millions)	(in millions)	September 30, 2022		Dec. 31, 2021		Balance Sheet Caption	September 30, 2022		Dec. 31, 2021		Balance Sheet Caption	(in millions)	September 30, 2023		December 31, 2022		Balance Sheet Caption	September 30, 2023		December 31, 2022		Balance Sheet Caption
Interest rate swaps designated as fair value hedges		$	—	$	87	Deferred income taxes and other assets	$	166	$	—	Post-employment obligations, deferred income taxes and other long-term liabilities
Interest rate swaps designated as fair value hedges:												Interest rate swaps designated as fair value hedges:
Non-current												Non-current	$	—	$	—	Deferred income taxes and other assets	$	158	$	136	Post-employment obligations, deferred income taxes and other long-term liabilities
Current												Current	—		—		Prepaid expenses and other receivables	13		20		Other accrued liabilities
Foreign currency forward exchange contracts:	Foreign currency forward exchange contracts:											Foreign currency forward exchange contracts:
Hedging instruments	Hedging instruments	760		222		Prepaid expenses and other receivables	66		65		Other accrued liabilities	Hedging instruments	254		304		Prepaid expenses and other receivables	63		96		Other accrued liabilities
Others not designated as hedges	Others not designated as hedges	148		70		Prepaid expenses and other receivables	141		32		Other accrued liabilities	Others not designated as hedges	113		108		Prepaid expenses and other receivables	115		130		Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary	Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	413		521		Long-term debt	Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	401		446		Long-term debt
		$	908	$	379		$	786	$	618			$	367	$	412		$	750	$	828

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2023

(Unaudited)

Note 11 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September 30, ~~2022~~2023 and ~~2021.~~2022.


		Gain (loss) Recognized in Other Comprehensive Income (loss)								Income (expense) and Gain (loss) Reclassified into Income										Gain (loss) Recognized in Other Comprehensive Income (loss)								Income (expense) and Gain (loss) Reclassified into Income
		Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended September 30				Nine Months Ended September 30						Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended September 30				Nine Months Ended September 30
(in millions)	(in millions)	2022		2021		2022		2021		2022		2021		2022		2021		Income Statement Caption	(in millions)	2023		2022		2023		2022		2023		2022		2023		2022		Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges	Foreign currency forward exchange contracts designated as cash flow hedges	$	350	$	96	$	442	$	142	$	79	$	(92)	$	149	$	(207)	Cost of products sold	Foreign currency forward exchange contracts designated as cash flow hedges	$	125	$	350	$	152	$	442	$	22	$	79	$	211	$	149	Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary	Debt designated as a hedge of net investment in a foreign subsidiary	24		4		108		41		—		—		—		—		n/a	Debt designated as a hedge of net investment in a foreign subsidiary	12		24		45		108		n/a		n/a		n/a		n/a		n/a
Interest rate swaps designated as fair value hedges	Interest rate swaps designated as fair value hedges	n/a		n/a		n/a		n/a		(85)		(14)		(253)		(81)		Interest expense	Interest rate swaps designated as fair value hedges	n/a		n/a		n/a		n/a		(18)		(85)		(15)		(253)		Interest expense

~~Table~~A gain of ~~Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2022~~

~~(Unaudited)~~

~~Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)~~

~~Losses of $27~~$60 million and ~~$18~~a loss of $27 million were recognized in the three months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. ~~Gains~~A loss of ~~$225~~$4 million and ~~$15~~a gain of $225 million were recognized in the first nine months ended September 30, ~~2022~~2023 and ~~2021,~~2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of September 30, ~~2022~~2023 and December 31, ~~2021~~2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.


		September 30, 2022				December 31, 2021					September 30, 2023				December 31, 2022
(in millions)	(in millions)	Carrying Value		Fair Value		Carrying Value		Fair Value		(in millions)	Carrying Value		Fair Value		Carrying Value		Fair Value
Long-term Investment Securities:	Long-term Investment Securities:									Long-term Investment Securities:
Equity securities	Equity securities	$	604	$	604	$	748	$	748	Equity securities	$	566	$	566	$	558	$	558
Other	Other	160		160		68		68		Other	222		222		208		208
Total Long-term Debt	Total Long-term Debt	(16,414)		(15,821)		(18,050)		(21,152)		Total Long-term Debt	(15,528)		(14,681)		(16,773)		(16,313)
Foreign Currency Forward Exchange Contracts:	Foreign Currency Forward Exchange Contracts:									Foreign Currency Forward Exchange Contracts:
Receivable position	Receivable position	908		908		292		292		Receivable position	367		367		412		412
(Payable) position	(Payable) position	(207)		(207)		(97)		(97)		(Payable) position	(178)		(178)		(226)		(226)
Interest Rate Hedge Contracts:	Interest Rate Hedge Contracts:									Interest Rate Hedge Contracts:
Receivable position	Receivable position	—		—		87		87		Receivable position	—		—		—		—
(Payable) position	(Payable) position	(166)		(166)		—		—		(Payable) position	(171)		(171)		(156)		(156)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

1718

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 911 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:


				Basis of Fair Value Measurement									Basis of Fair Value Measurement
(in millions)	(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
September 30, 2022:
September 30, 2023:										September 30, 2023:
Equity securities	Equity securities	$	293	$	293	$	—	$	—	Equity securities	$	304	$	304	$	—	$	—
Foreign currency forward exchange contracts	Foreign currency forward exchange contracts	908		—		908		—		Foreign currency forward exchange contracts	367		—		367		—
Total Assets	Total Assets	$	1,201	$	293	$	908	$	—	Total Assets	$	671	$	304	$	367	$	—

Fair value of hedged long-term debt	Fair value of hedged long-term debt	$	2,685	$	—	$	2,685	$	—	Fair value of hedged long-term debt	$	2,702	$	—	$	2,702	$	—
Interest rate swap derivative financial instruments	Interest rate swap derivative financial instruments	166		—		166		—		Interest rate swap derivative financial instruments	171		—		171		—
Foreign currency forward exchange contracts	Foreign currency forward exchange contracts	207		—		207		—		Foreign currency forward exchange contracts	178		—		178		—
Contingent consideration related to business combinations	Contingent consideration related to business combinations	138		—		—		138		Contingent consideration related to business combinations	109		—		—		109
Total Liabilities	Total Liabilities	$	3,196	$	—	$	3,058	$	138	Total Liabilities	$	3,160	$	—	$	3,051	$	109

December 31, 2021:
December 31, 2022:										December 31, 2022:
Equity securities	Equity securities	$	402	$	402	$	—	$	—	Equity securities	$	307	$	307	$	—	$	—
Interest rate swap derivative financial instruments		87		—		87		—

Foreign currency forward exchange contracts	Foreign currency forward exchange contracts	292		—		292		—		Foreign currency forward exchange contracts	412		—		412		—
Total Assets	Total Assets	$	781	$	402	$	379	$	—	Total Assets	$	719	$	307	$	412	$	—

Fair value of hedged long-term debt	Fair value of hedged long-term debt	$	2,926	$	—	$	2,926	$	—	Fair value of hedged long-term debt	$	2,691	$	—	$	2,691	$	—
Interest rate swap derivative financial instruments										Interest rate swap derivative financial instruments	156				156
Foreign currency forward exchange contracts	Foreign currency forward exchange contracts	97		—		97		—		Foreign currency forward exchange contracts	226		—		226		—
Contingent consideration related to business combinations	Contingent consideration related to business combinations	130		—		—		130		Contingent consideration related to business combinations	130		—		—		130
Total Liabilities	Total Liabilities	$	3,153	$	—	$	3,023	$	130	Total Liabilities	$	3,203	$	—	$	3,073	$	130

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of contingent consideration from December 31, 2022 reflects the impact of projected timeline changes for events that will trigger payment of contingent consideration, partially offset by additional contingent consideration due to a recent business acquisition.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2023

(Unaudited)

Note 1012 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2022~~

~~(Unaudited)~~

~~Note 10 — Litigation and Environmental Matters (Continued)~~

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately ~~$40~~$25 million to ~~$50~~$35 million. The recorded accrual balance at September 30, ~~2022~~2023 for these proceedings and exposures was approximately ~~$45~~$30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 1113 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:


		Defined Benefit Plans								Medical and Dental Plans									Defined Benefit Plans								Medical and Dental Plans
		Three Months Ended Sept. 30				Nine Months Ended Sept. 30				Three Months Ended Sept. 30				Nine Months Ended Sept. 30					Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended September 30				Nine Months Ended September 30
(in millions)	(in millions)	2022		2021		2022		2021		2022		2021		2022		2021		(in millions)	2023		2022		2023		2022		2023		2022		2023		2022
Service cost - benefits earned during the period	Service cost - benefits earned during the period	$	92	$	98	$	282	$	294	$	13	$	14	$	38	$	42	Service cost - benefits earned during the period	$	56	$	92	$	174	$	282	$	10	$	13	$	29	$	38
Interest cost on projected benefit obligations	Interest cost on projected benefit obligations	74		62		225		186		9		8		27		25		Interest cost on projected benefit obligations	114		74		342		225		15		9		45		27
Expected return on plan assets	Expected return on plan assets	(231)		(211)		(701)		(633)		(8)		(6)		(23)		(20)		Expected return on plan assets	(244)		(231)		(729)		(701)		(6)		(8)		(18)		(23)
Curtailment gain																		Curtailment gain	—		—		(14)		—		—		—		—		—
Net amortization of:	Net amortization of:																	Net amortization of:
Actuarial loss, net	Actuarial loss, net	58		79		174		238		2		7		8		21		Actuarial loss, net	2		58		8		174		(1)		2		(2)		8
Prior service cost (credit)	Prior service cost (credit)	—		—		1		1		(6)		(7)		(18)		(21)		Prior service cost (credit)	1		—		1		1		(3)		(6)		(10)		(18)
Net cost (credit)	Net cost (credit)	$	(7)	$	28	$	(19)	$	86	$	10	$	16	$	32	$	47	Net cost (credit)	$	(71)	$	(7)	$	(218)	$	(19)	$	15	$	10	$	44	$	32

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2023 and 2022, ~~and 2021, $362~~$302 million and ~~$366~~$362 million, respectively, were contributed to defined benefit plans. In the first nine months of ~~2022~~2023 and ~~2021,~~2022, $28 million~~and$26 million, respectively~~, ~~were~~ was contributed, in each year, to the post-employment medical and dental plans.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2023

(Unaudited)

Note 1214 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of ~~2022~~2023 and ~~2021,~~2022, taxes on earnings include approximately ~~$36~~$11 million and ~~$97~~$36 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2023 and 2022, taxes on earnings also include approximately $59 million and $20 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately ~~$75 million to $100~~$55 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and unsupported. Abbott expects to file a petition with the U.S. Tax Court contesting the 2019 SNOD in December of 2023.

Abbott’s 2017 and 2018 Federal tax years are also currently under examination by the IRS with respect to income reallocation issues similar to those included in the 2019 Federal tax year. Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through litigation as necessary.

Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues to believe that its reserves for uncertain tax positions are appropriate.

The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1 proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2 proposes to assess a 15% minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have indicated their intent to adopt the proposal and are drafting legislation to implement the Pillar 2 model rules with a subset of the rules becoming effective January 1, 2024, and the remaining rules becoming effective January 1, 2025, or in later periods. Abbott is also continuing to analyze the Pillar 2 model rules. Implementation of the OECD proposal may have a material impact on Abbott’s Condensed Consolidated Financial Statements in the future.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 1315 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories ~~physician offices~~ and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

2022

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, ~~2022~~2023

(Unaudited)

Note 1315 — Segment Information (Continued)

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.


		Net Sales to External Customers								Operating Earnings									Net Sales to External Customers								Operating Earnings
		Three Months Ended Sept. 30				Nine Months Ended Sept. 30				Three Months Ended Sept. 30				Nine Months Ended Sept. 30					Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended September 30				Nine Months Ended September 30
(in millions)	(in millions)	2022		2021		2022		2021		2022		2021		2022		2021		(in millions)	2023		2022		2023		2022		2023		2022		2023		2022
Established Pharmaceutical Products	Established Pharmaceutical Products	$	1,326	$	1,265	$	3,696	$	3,515	$	331	$	293	$	831	$	682	Established Pharmaceutical Products	$	1,368	$	1,326	$	3,844	$	3,696	$	345	$	331	$	952	$	831
Nutritional Products	Nutritional Products	1,795		2,108		5,642		6,252		69		431		550		1,388		Nutritional Products	2,073		1,795		6,116		5,642		284		69		972		550
Diagnostic Products	Diagnostic Products	3,671		3,912		13,279		11,173		1,352		1,652		5,631		4,429		Diagnostic Products	2,449		3,641		7,454		13,192		632		1,346		1,720		5,615
Medical Devices	Medical Devices	3,615		3,632		10,937		10,618		1,039		1,160		3,272		3,375		Medical Devices	4,249		3,645		12,444		11,024		1,342		1,045		3,805		3,288
Total Reportable Segments	Total Reportable Segments	10,407		10,917		33,554		31,558		2,791		3,536		10,284		9,874		Total Reportable Segments	10,139		10,407		29,858		33,554		2,603		2,791		7,449		10,284
Other	Other	3		11		8		49										Other	4		3		10		8
Net sales	Net sales	$	10,410	$	10,928	$	33,562	$	31,607									Net sales	$	10,143	$	10,410	$	29,868	$	33,562
Corporate functions and benefit plan costs	Corporate functions and benefit plan costs									(115)		(204)		(352)		(450)		Corporate functions and benefit plan costs									(50)		(115)		(198)		(352)
Net interest expense	Net interest expense									(86)		(123)		(309)		(370)		Net interest expense									(69)		(86)		(182)		(309)
Share-based compensation (a)	Share-based compensation (a)									(123)		(114)		(570)		(534)		Share-based compensation (a)									(117)		(123)		(530)		(570)
Amortization of intangible assets	Amortization of intangible assets									(498)		(520)		(1,517)		(1,533)		Amortization of intangible assets									(496)		(498)		(1,485)		(1,517)
Other, net (b)	Other, net (b)									(211)		(82)		(550)		(1,103)		Other, net (b)									(200)		(211)		(185)		(550)
Earnings before taxes	Earnings before taxes									$	1,758	$	2,493	$	6,986	$	5,884	Earnings before taxes									$	1,671	$	1,758	$	4,869	$	6,986


Notes:			Three and nine months ended September 30, 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.


(b)			Other, net for the three months and nine months ended September 30, 2023 includes costs associated with the acquisition of CSI and charges related to restructuring actions and intangible asset and investment impairments. Other, net for the nine months ended September 30, 2023 also includes income arising from fair value changes in contingent consideration related to previous business combinations. Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment, ~~and~~ $111 million of charges related to the impairment of IPR&D intangible ~~assets. Other, net for the three and nine months ended September 30, 2022 and 2021 also includes~~assets as well as integration costs ~~associated with~~related to the acquisition of Alere Inc. and restructuring charges. Restructuring charges in 2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes costs related to certain litigation.

2123

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review — Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.


	Net Sales to External Customers
(in millions)	Three Months Ended September 30, 2023		Three Months Ended September 30, 2022		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	1,368	$	1,326	3.2	%	(7.9)	%	11.1	%
Nutritional Products	2,073		1,795		15.5		(1.4)		16.9
Diagnostic Products	2,449		3,641		(32.7)		(0.8)		(31.9)
Medical Devices	4,249		3,645		16.6		0.6		16.0
Total Reportable Segments	10,139		10,407		(2.6)		(1.4)		(1.2)
Other	4		3		n/m		n/m		n/m
Net Sales	$	10,143	$	10,410	(2.6)		(1.4)		(1.2)

Total U.S.	$	3,817	$	4,094	(6.8)		—		(6.8)

Total International	$	6,326	$	6,316	0.2		(2.2)		2.4


		Net Sales to External Customers											Net Sales to External Customers
(in millions)	(in millions)	Three Months Ended September 30, 2022		Three Months Ended September 30, 2021		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange		(in millions)	Nine Months Ended September 30, 2023		Nine Months Ended September 30, 2022		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	Established Pharmaceutical Products	$	1,326	$	1,265	4.9	%	(7.3)	%	12.2	%	Established Pharmaceutical Products	$	3,844	$	3,696	4.0	%	(7.6)	%	11.6	%
Nutritional Products	Nutritional Products	1,795		2,108		(14.9)		(4.6)		(10.3)		Nutritional Products	6,116		5,642		8.4		(2.8)		11.2
Diagnostic Products	Diagnostic Products	3,671		3,912		(6.2)		(5.6)		(0.6)		Diagnostic Products	7,454		13,192		(43.5)		(1.4)		(42.1)
Medical Devices	Medical Devices	3,615		3,632		(0.5)		(6.9)		6.4		Medical Devices	12,444		11,024		12.9		(1.7)		14.6
Total Reportable Segments	Total Reportable Segments	10,407		10,917		(4.7)		(6.0)		1.3		Total Reportable Segments	29,858		33,554		(11.0)		(2.4)		(8.6)
Other	Other	3		11		n/m		n/m		n/m		Other	10		8		n/m		n/m		n/m
Net Sales	Net Sales	$	10,410	$	10,928	(4.7)		(6.0)		1.3		Net Sales	$	29,868	$	33,562	(11.0)		(2.4)		(8.6)

Total U.S.	Total U.S.	$	4,094	$	4,368	(6.3)		—		(6.3)		Total U.S.	$	11,503	$	13,923	(17.4)		—		(17.4)

Total International	Total International	$	6,316	$	6,560	(3.7)		(10.0)		6.3		Total International	$	18,365	$	19,639	(6.5)		(4.1)		(2.4)

Notes:

The Acelis Connected Health business was internally transferred from Diagnostic Products to Medical Devices on January 1, 2023. As a result, $30 million of sales in the third quarter of 2022 and $87 million in the first nine months of 2022 were moved from Diagnostic Products to Medical Devices.

In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Net Sales to External Customers
(in millions) Nine Months Ended
September 30, 2022 Nine Months Ended
September 30, 2021 Total
Change Impact of
Foreign
Exchange Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products $ 3,696 $ 3,515 5.2 % (6.4) % 11.6 %
Nutritional Products 5,642 6,252 (9.8) (3.4) (6.4)
Diagnostic Products 13,279 11,173 18.9 (4.2) 23.1
Medical Devices 10,937 10,618 3.0 (5.4) 8.4
Total Reportable Segments 33,554 31,558 6.3 (4.7) 11.0
Other 8 49 n/m n/m n/m
Net Sales $ 33,562 $ 31,607 6.2 (4.7) 10.9
Total U.S. $ 13,923 $ 11,787 18.1 — 18.1
Total International $ 19,639 $ 19,820 (0.9) (7.4) 6.5

~~Notes:~~

n/m = Percent change is not meaningful

2224

Table of Contents

The ~~1.3~~1.2 percent ~~increase~~decrease in total net sales during the third quarter of ~~2022,~~2023, excluding the impact of foreign exchange, reflected ~~growth~~the decrease in ~~the Medical Devices and Established Pharmaceutical Products segments~~demand for Abbott’s rapid diagnostic tests to detect COVID-19, partially offset by ~~lower Nutritional Products sales as well as a year-over-year decline in COVID-19 testing-related revenues.~~higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $305 million during the third quarter of 2023 and approximately $1.7 billion during the third quarter of ~~2022 and approximately $1.9 billion during the third quarter of 2021.~~2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales ~~decreased 3.1~~increased 12.6 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased ~~3.2~~14.1 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the third quarter as the relatively stronger U.S. dollar decreased total international sales by ~~10.0~~2.2 percent and total sales by ~~6.0~~1.4 percent.

The ~~10.9~~8.6 percent ~~increase~~decrease in total net sales during the first nine months of ~~2022,~~2023, excluding the impact of foreign exchange, reflected lower demand for Abbott’s ~~rapid diagnostic~~COVID-19 tests, ~~to detect COVID-19 as well as growth in the Medical Devices and Established Pharmaceutical Products segments~~ partially offset by ~~lower Nutritional Products sales.~~higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $1.3 billion during the first nine months of 2023 and approximately $7.3 billion during the first nine months of ~~2022 and approximately $5.4 billion during the first nine months of 2021.~~2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased ~~0.1~~8.8 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased ~~4.9~~11.8 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first nine months as the relatively stronger U.S. dollar decreased total international sales by ~~7.4~~4.1 percent and total sales by ~~4.7~~2.4 percent.

Due to the unpredictability of ~~the duration and impact of the current~~demand for COVID-19 ~~pandemic,~~tests, the future extent to which ~~the~~ COVID-19 ~~pandemic~~ will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.

The table below provides detail by sales category for the nine months ended September ~~30.~~30, 2023. Percent changes are versus the prior year and are based on unrounded numbers.


(in millions)	(in millions)	Sept. 30, 2022		Sept. 30, 2021		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange		(in millions)	September 30, 2023		September 30, 2022		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange
Established Pharmaceutical Products —	Established Pharmaceutical Products —											Established Pharmaceutical Products —
Key Emerging Markets	Key Emerging Markets	$	2,826	$	2,672	5.8	%	(6.4)	%	12.2	%	Key Emerging Markets	$	2,889	$	2,853	1.3	%	(8.7)	%	10.0	%
Other Emerging Markets	Other Emerging Markets	870		843		3.2		(6.3)		9.5		Other Emerging Markets	955		843		13.2		(3.9)		17.1

Nutritionals —	Nutritionals —											Nutritionals —
International Pediatric Nutritionals	International Pediatric Nutritionals	1,491		1,637		(8.9)		(4.3)		(4.6)		International Pediatric Nutritionals	1,477		1,491		(0.9)		(3.8)		2.9
U.S. Pediatric Nutritionals	U.S. Pediatric Nutritionals	1,108		1,622		(31.7)		—		(31.7)		U.S. Pediatric Nutritionals	1,472		1,108		32.8		—		32.8
International Adult Nutritionals	International Adult Nutritionals	2,027		1,987		2.0		(7.0)		9.0		International Adult Nutritionals	2,086		2,027		2.9		(5.0)		7.9
U.S. Adult Nutritionals	U.S. Adult Nutritionals	1,016		1,006		1.0		—		1.0		U.S. Adult Nutritionals	1,081		1,016		6.4		—		6.4

Diagnostics —	Diagnostics —											Diagnostics —
Core Laboratory	Core Laboratory	3,624		3,780		(4.1)		(5.7)		1.6		Core Laboratory	3,789		3,624		4.6		(3.5)		8.1
Molecular	Molecular	815		1,082		(24.7)		(2.8)		(21.9)		Molecular	421		815		(48.4)		(0.9)		(47.5)
Point of Care	Point of Care	394		401		(1.6)		(1.2)		(0.4)		Point of Care	416		394		5.5		(0.4)		5.9
Rapid Diagnostics	Rapid Diagnostics	8,446		5,910		42.9		(3.8)		46.7		Rapid Diagnostics	2,828		8,359		(66.2)		(0.6)		(65.6)

Medical Devices —	Medical Devices —											Medical Devices —
Rhythm Management	Rhythm Management	1,605		1,657		(3.2)		(4.5)		1.3		Rhythm Management	1,673		1,605		4.3		(1.7)		6.0
Electrophysiology	Electrophysiology	1,440		1,403		2.6		(5.6)		8.2		Electrophysiology	1,602		1,440		11.3		(2.8)		14.1
Heart Failure	Heart Failure	690		650		6.2		(2.4)		8.6		Heart Failure	860		777		10.7		(0.2)		10.9
Vascular	Vascular	1,878		1,976		(5.0)		(4.9)		(0.1)		Vascular	2,004		1,878		6.7		(2.1)		8.8
Structural Heart	Structural Heart	1,271		1,191		6.7		(6.1)		12.8		Structural Heart	1,446		1,271		13.8		(1.5)		15.3
Neuromodulation	Neuromodulation	568		584		(2.7)		(2.1)		(0.6)		Neuromodulation	650		568		14.4		(1.1)		15.5
Diabetes Care	Diabetes Care	3,485		3,157		10.4		(7.0)		17.4		Diabetes Care	4,209		3,485		20.8		(1.5)		22.3

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $87 million of sales for the first nine months of 2022 were moved from Rapid Diagnostics to Heart Failure.

2325

Table of Contents

Excluding the unfavorable effect of foreign exchange, sales in ~~the~~ Key Emerging Markets for Established Pharmaceutical Products increased ~~12.2~~10.0 percent in the first nine months of ~~2022,~~2023, led by ~~double-digit~~ growth in several countries ~~including India~~ and ~~China, and~~across several therapeutic areas,including ~~gastroenterology,~~cardiometabolic, women's health,and central nervous system/pain ~~management, and respiratory products.~~management. Other Emerging Markets, excluding the effect of foreign exchange, increased by ~~9.5~~17.1 percent in the first nine months of ~~2022.~~2023.

~~International Pediatric Nutritional sales, excluding~~Excluding the ~~effect~~impact of foreign exchange, ~~decreased 4.6 percent~~total Nutritional Products sales in the first nine months of ~~2022 versus the comparable 2021 period.~~2023 increased 11.2 percent. The decrease reflects the impact of challenging market dynamics in the infant category in Greater China partially offset by higher sales volumes in various countries in Southeast Asia and Latin America. International Adult Nutritional sales, excluding the effect of foreign exchange, increased 9.032.8 percent ~~reflecting double digit growth of the Ensure~~® ~~and Glucerna~~® ~~brands in several countries in Southeast Asia and China. In the first nine months of 2022, U.S. Adult Nutritional sales increased 1.0 percent.~~

In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall in February 2022 of certain infant powder formula products manufactured at its facility in Sturgis, Michigan and stopped production at the facility. On May 16, 2022, Abbott entered into a consent decree with the U.S. Food and Drug Administration (FDA) on the steps necessary to resume production and maintain the Sturgis facility and operations. On July 1, Abbott restarted partial production at the facility starting with its specialty formula EleCare® ~~and metabolic formulas. Subsequently, Abbott restarted Similac~~® ~~production. The consent decree does not affect any other Abbott plant or operation.~~

During the first three quarters of 2022, Abbott took various actions to mitigate the impact of the recall on the supply of formula in the U.S. These actions included the shipment of infant formula powder into the U.S. from Abbott's FDA-registered facility in Ireland; prioritization of infant formula production at its Columbus, Ohio facility; conversion of other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed product; increased production of powder infant formula at its Casa Grande, Arizona manufacturing site; and importation of product from its facility in Spain as permitted by the FDA.

~~The 31.7 percent decrease~~increase in U.S. Pediatric Nutritional sales in the first nine months of 2023 reflects progress in recovering market share in 2023 following the voluntary recall of certain infant formula products in the first quarter of 2022, ~~reflects~~as well as the unfavorable 2022 impact of the recall, ~~and the Sturgis production stoppage~~ partially offset by ~~increased demand for Abbott’s~~a decrease in 2023 Pedialyte® ~~products. U.S.~~sales. Excluding the effect of foreign exchange, the 2.9 percent increase in International Pediatric Nutritional sales ~~of infant powder formula brands associated with the recall were $277 million and $900 million~~ in the first nine months of ~~2022~~2023 primarily reflects growth in various markets, partially offset by the impact of exiting the pediatric nutrition business in China. The increases of 6.4 percent in U.S. Adult Nutritionals and ~~2021, respectively.~~7.9 percent, excluding the effect of foreign exchange, in International Adult Nutritionals in the first nine months of 2023 were led by growth of Ensure® and Glucerna® products.

The ~~23.1~~42.1 percent ~~increase~~decrease in Diagnostic Products sales in the first nine months of ~~2022,~~2023, excluding the impact of foreign exchange, was driven by lower demand for ~~Abbott’s portfolio of~~ COVID-19 ~~tests in~~tests. In Rapid Diagnostics, ~~and growth in routine diagnostic testing in Molecular Diagnostics. In Core Laboratory Diagnostics,~~ sales ~~increased 1.6~~decreased 65.6 percent in the first nine months of 2023, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first nine months of 2023 and 2022, Rapid Diagnostics COVID-19 testing-related sales were $1.2 billion and $6.9 billion, respectively. In the first nine months of 2023, Rapid Diagnostics sales increased 6.5 percent, excluding COVID-19 testing-related sales, and increased 8.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Core Laboratory Diagnostics, sales increased 8.1 percent in the first nine months of 2023, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing ~~from the continued roll-out of the Alinity~~® ~~platform~~performed in hospitals and ~~an expanded menu of tests. These increases were~~other laboratories, partially offset by lower test sales ~~of Abbott’s laboratory-based tests~~ for the detection of COVID-19 IgG and IgM antibodies, which determine if someone was previously infected with the COVID-19 virus, as well as market disruptions in China due to COVID-19 quarantine restrictions in various cities primarily during the second quarter of 2022.antibodies. In the first nine months of ~~2022~~2023 and ~~2021,~~2022, Core Laboratory Diagnostics ~~IgG and IgM antibody~~COVID-19 testing-related sales ~~on Abbott’s ARCHITECT and Alinity i platforms~~ were ~~$51~~$16 million and ~~$159~~$51 million, respectively. In the first nine months of ~~2022,~~2023, Core Laboratory Diagnostics sales ~~decreased 1.3~~increased 5.6 percent, excluding COVID-19 testing-related sales, and increased ~~4.6~~9.2 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales. In the third quarter of 2023, Core Laboratory Diagnostics received U.S. Food and Drug Administration (FDA) clearance for its Alinity® h-series hematology system, which integrates hematology workflow from high-throughput Complete Blood Count analysis to automated slide making and staining.

The ~~21.9~~47.5 percent decrease in Molecular Diagnostics sales in the first nine months of ~~2022,~~2023, excluding the effect of foreign exchange, was driven by lower demand for ~~Abbott’s~~ laboratory-based molecular tests for COVID-19, ~~partially offset by growth~~as well as lower demand for respiratory testing compared to significantly higher-than-usual demand in the ~~base business from increased routine molecular testing~~.first nine months of 2022. In the first nine months of ~~2022~~2023 and ~~2021,~~2022, Molecular Diagnostics COVID-19 testing-related sales were ~~$375~~$36 million and ~~$699~~$375 million, respectively. In the first nine months of ~~2022,~~2023, Molecular Diagnostics sales ~~increased 14.9~~decreased 12.8 percent, excluding COVID-19 testing-related sales, and ~~increased 19.4~~decreased 11.3 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Rapid Diagnostics, sales increased 46.7 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the demand for Abbott’s COVID-19 tests on its rapid testing platforms, including the Panbio® ~~system, the ID NOW~~® ~~platform, and the BinaxNOW~~® COVID-19 Ag Card test. In the first nine months of 2022 and 2021, Rapid Diagnostics COVID-19 testing-related sales were $6.9 billion and $4.5 billion, respectively. In the first nine months of 2022, Rapid Diagnostics sales increased 11.8 percent, excluding COVID-19 testing-related sales, and increased 14.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.~~These increases reflect higher sales~~

~~Table of Contents~~

~~of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in various other Rapid Diagnostics products.~~

Excluding the effect of foreign exchange, total Medical Devices sales grew ~~8.4~~14.6 percent in the first nine months of ~~2022, driven~~2023, led by double-digit growth in Diabetes Care, ~~Electrophysiology,~~ Structural Heart, Heart Failure, Neuromodulation and ~~Heart Failure. Growth in~~Electrophysiology. Higher Diabetes Care sales ~~was~~were driven by continued growth of FreeStyle Libre®, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled ~~$3.1~~$3.9 billion in the first nine months of ~~2022,~~2023, which reflected a ~~22.8~~26.2 percent increase, excluding the effect of foreign exchange, over the first nine months of ~~2021~~2022 when FreeStyle Libre sales totaled ~~$2.7~~$3.1 billion. ~~During the third quarter of 2022, Abbott launched its FreeStyle Libre 3 system in the U.S., which automatically delivers up-to-the-minute glucose readings and 14-day accuracy in a wearable sensor.~~

During the first nine months of ~~2022,~~2023, procedure volumes increased across ~~Abbott’s~~the cardiovascular and neuromodulation ~~businesses were negatively impacted by new surges of COVID-19~~businesses. In Structural Heart, the 15.3 percent increase in various geographies as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges throughout the nine months. Despite such challenges, overall volume trends improved in several businesses versus the first nine months of 2021. In Electrophysiology, the 8.2 percent growth,sales, excluding the effect of foreign exchange, reflects continued growth of the ~~increase in procedure volumes and the continued roll‑out of Abbott’s EnSite~~MitraClip® ~~X EP System~~productalong with ~~Ensite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S., Japan and across Europe. In January 2022, Abbott announced FDA clearance for the EnSite~~contributions from various products, including Amulet® ~~X EP System with EnSite OT. The system leverages the Advisor~~, Navitor® ~~HD Grid Catheter to provide a 360‑degree view~~, and TriClip®. In Vascular, the 8.8 percent increase in sales, excluding the impact of ~~the heart without regard to the orientation of the catheter in the heart.~~

~~Growth in Structural Heart~~foreign exchange, during the first nine months of ~~2022,~~2023 reflects the acquisition of Cardiovascular Systems, Inc. (CSI) on April 27, 2023, as well as double-digit growth in endovascular sales.

In Electrophysiology, the 14.1 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher procedure volumes inthe U.S., China, and various European countries. In Neuromodulation, the 15.5 percent increase in sales, excluding the effect of foreign exchange, was ~~12.8 percent,~~ driven by ~~growth across several areas~~the recent launch of the ~~business, including Amplatzer~~®_~~Amulet~~Eterna® ~~Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage, an area in the heart where blood clots can form and MitraClip~~®~~, Abbott's market-leading device~~rechargeable spinal cord stimulation system for the ~~minimally invasive~~ treatment of mitral regurgitation, a leaky heart valve. In Vascular, sales during the first nine months of 2022, excluding the impact of foreign exchange, were virtually unchanged as higher endovascular sales were offset by the negative effect of lower average pricing for drug-eluting stents (DES) in the U.S. and a lag in the recovery of percutaneous coronary intervention case rateschronic pain along with market growth compared to ~~many other cardiovascular procedures.~~the prior year period.

Table of Contents

In the first nine months of ~~2022,~~2023, Medical Devices received various ~~other~~ product approvals. In ~~February 2022,~~January 2023, Abbott announced that the U.S. FDA had approved Navitor, Abbott's second-generation transcatheter aortic valve implantation system to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. In March 2023, Abbott's Freestyle Libre continuous glucose monitoring system received U.S. FDA ~~approval~~clearance for ~~an expanded indication for its CardioMEMS~~integration with automated insulin delivery systems. In March 2023, the U.S. FDA approved Abbott's Epic® ~~HF system, a small implantable sensor and remote monitoring system that can detect early warning signs of worsening heart failure.~~Max stented tissue valve to treat people with aortic regurgitation or stenosis. In ~~April 2022,~~May 2023, Abbott ~~announced~~received U.S. FDA approval ~~for~~of its ~~Aveir~~TactiFlex® ~~single-chamber~~Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a flexible electrode tip and contact force sensing technology to treat patients with atrial fibrillation. In June 2023, Abbott received U.S. FDA approval of its AVEIR™dual chamber leadless pacemaker ~~for~~system, the ~~treatment of patients in the U.S.~~world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. In July 2023, Abbott obtained CE Mark for its AVEIR single-chamber leadless pacemaker.

The gross profit margin percentage was 49.7 percent for the third quarter of 2023 compared to 50.7 percent for the third quarter of 2022 ~~compared to 54.8~~and 50.1 percent for the ~~third quarter~~first nine months of 2021. The decrease reflects the continued impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business during the first half of 2022 as well as the prioritization of infant formula sales related2023 compared to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). The decrease also reflects higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses as well as lower COVID-19 testing-related sales in 2022 and the nonrecurrence of a favorable change in estimate in the third quarter of 2021 related to a previously recognized restructuring plan.

~~The gross profit margin was~~ 52.1 percent for the first nine months of ~~2022 compared to 51.6 percent for~~2022. The decrease in the third quarter and first nine months of ~~2021. The increase~~2023 reflects the ~~nonrecurrence~~unfavorable effects of ~~2021 restructuring charges and the impact of higher~~lower sales of COVID-19 ~~rapid~~ tests, ~~during the first nine months of 2022. These favorable impacts were~~foreign exchange, and higher costs for various manufacturing inputs, partially offset by the impact in 2022 of the voluntary product recall ~~and Sturgis manufacturing stoppage~~ in the Nutritional business ~~as well as higher manufacturing~~ and supply chain costs across Abbott's businesses, including inflation and higher commodity and distribution expenses. The future extent to which inflation, supply chain disruptions, and unfavorable foreign exchange rates will have a material effect on Abbott's operating results is uncertain.the impact in 2023 of gross margin improvement initiatives.

Research and development (R&D) expenses ~~increased~~decreased $110 million, or ~~16.2~~14.0 percent, in the third quarter of ~~2022~~2023 and ~~increased $183~~decreased $122 million, or ~~9.2~~5.6 percent, in the first nine months of ~~2022~~2023 compared to the prior year. The ~~increase~~decrease in R&D expense in the third quarter and first nine months of 2023 was primarily ~~reflects~~driven by the non-recurrence of an impairment ~~of certain~~charge recognized in 2022 related to in-process R&D ~~intangible~~ assets acquired in the third quarter of 2022. The increase in the first nine months was also driven by higher spending on various projects to advance products in development partially offset by the favorable impact of foreign exchange.a previous business combination.

~~Table of Contents~~

Selling, general and administrative ~~(SG&A)~~ expenses decreased ~~$36~~$8 million, or ~~1.3~~0.3 percent, in the third quarter of ~~2022~~2023, and decreased $50 million, or 0.6 percent, in the first nine months of 2023 compared to the prior ~~year as higher~~year. Higher selling and marketing spending to drive growth across various businesses was ~~more than~~ offset by the favorable impact of foreign exchange. ~~SG&A~~The decrease during the first nine months of 2023 also reflects the non-recurrence of 2022 expenses ~~were virtually unchanged~~related to the voluntary product recall in the Nutritional segment.

Interest Expense, net

Interest expense, net decreased from $86 million in the third quarter of 2022 to $69 million in the third quarter of 2023 and decreased from $309 million in the first nine months of 2022 ~~compared~~ to $182 million in the ~~prior year as higher selling and marketing spending was offset by the nonrecurrence~~first nine months of ~~certain 2021 litigation costs and~~2023. The decreases were due to the favorable impact of ~~foreign exchange.~~higher interest rates on interest income, partially offset by the negative impact of interest rate hedge contracts related to certain fixed-rate debt.

Other (Income) Expense, net

Other income, net ~~increased~~decreased from ~~$74 million of income in the third quarter of 2021 to~~ $93 million of income in the third quarter of 2022 ~~and from $214~~to $83 million of income in the ~~first nine months~~third quarter of ~~2021 to~~2023 and increased from $253 million of income in the first nine months of ~~2022. The increases~~2022 to $370 million of income in the first nine months of 2023. The third quarter and the first nine months of ~~2022 were primarily due to~~ 2023 reflecthigher income in ~~2022~~2023 related to the non-service cost components of net pension and post-retirement medical benefit costs. In the first nine months of 2022, the higher year-to-date income related to the non-service cost components was partially offset by the nonrecurrence of a gain on the sale of an equity method investment that occurred in the second quarter of 2021.

~~Interest Expense, net~~

~~Interest expense, net declined $37 million in the~~ third quarter of ~~2022 and $61 million~~2023, the decline in ~~the first nine months of 2022 versus 2021~~Other income, net is due to ~~the impact of~~ higher ~~interest rates and cash and short-term investment balances on interest income and the repayment of debt in the first quarter of 2022 partially offset by the impact of interest rate hedge contracts~~impairment charges related to ~~certain fixed-rate debt.~~long term investments that more than offset the increase in income associated with the non-service component of pension and post-retirement medical plans.

Taxes on Earnings

Table of Contents

Liquidity and Capital Resources September 30, ~~2022~~2023 Compared with December 31, ~~2021~~2022

The decrease in cash and cash equivalents from ~~$9.8~~$9.9 billion at December 31, ~~2021~~2022 to ~~$9.6~~$6.7 billion at September 30, ~~2022~~2023 primarily reflects ~~share repurchases,~~ the payment of dividends, ~~capital expenditures, and~~ the repayment of debt, share repurchases, the cost of business acquisitions and capital expenditures, partially offset by the cash generated from operations in the first nine months of ~~2022.~~2023. Working capital was ~~$11.5~~$9.6 billion at September 30, ~~2022~~2023 and ~~$11.1~~$9.7 billion at December 31, ~~2021.~~2022. The ~~increase~~decrease in working capital in ~~2022~~2023 primarily reflects ~~an increase~~a decrease in ~~inventory partially~~cash and cash equivalents, which was nearly offset by ~~an increase~~increases in accounts receivables and inventory and decreases in the current portion of long-term debt, accounts payable and ~~a decrease in cash and cash equivalents.~~other accrued liabilities.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of ~~2022~~2023 totaled approximately ~~$7.3~~$4.2 billion, a decrease of ~~$211 million~~$3.0 billion from the prior ~~year~~year. The decrease is primarily due to the decline in operating earnings and an ~~increased investment~~increase in ~~working capital partially offset by higher operating earnings.~~cash taxes paid. Net cash from operating activities in 2023 includes $302 million of pension contributions and the payment of cash taxes of approximately $1.180 billion. Net cash from operating activities in 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 ~~million in 2022. Net cash from operating activities includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million in 2021.~~million.

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of September 30, ~~2022,~~2023, $2.15 billion of the $5 billion authorization remains available.

At September 30, ~~2022,~~2023, Abbott’s long-term debt rating was AA- by ~~Standard & Poor’s Corporation~~S&P Global Ratings and A1Aa3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.

2628

Table of Contents

In December 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott’s common shares from time to time. The new authorization was in addition to the $1.081 billion portion of the share repurchase program authorized in 2019 that was unused as of December 31, 2021.In the first nine months of ~~2022,~~2023, Abbott repurchased ~~25.7~~approximately 7 million of its common shares for ~~$2.965 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021 authorization.~~$725 million. As of September 30, ~~2022, $3.116~~2023, $1.709 billion remains available for repurchase under the ~~2021~~share repurchase ~~program.~~program authorized by the board of directors in December 2021.

In each of the first three quarters of ~~2022,~~2023, Abbott declared a quarterly dividend of ~~$0.47~~$0.51 per share on its common shares, which represents an increase of ~~4.4~~8.5 percent over the ~~$0.45~~$0.47 per share dividend declared in each of the first three quarters of ~~2021.~~2022.

Business Acquisitions

On April 27, 2023, Abbott completed the acquisition of CSI for $20 per common share, which equated to a purchase price of $851 million. The transaction was funded with cash on hand and accounted for as a business combination. CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the ~~2021~~2022 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

2729

Table of Contents

PART I. FINANCIAL INFORMATION

Item 4. Controls and Procedures

(a)Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, ~~Robert E. Funck, Jr.,~~Philip P. Boudreau, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)Changes in internal control over financial reporting. During the quarter ended September 30, ~~2022,~~2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, ~~2021 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31,~~ 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

Period
(a) Total
Number of
Shares (or
Units)
Purchased(1)
(b) Average
Price Paid per
Share (or
Unit) (c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs(2)
July 1, 2022 - July 31, 2022 — $ — — $ 3,981,169,070
August 1, 2022 - August 31, 2022 1,050,000 102.567 1,050,000 3,873,473,475
September 1, 2022 - September 30, 2022 7,363,597 102.895 7,363,597 3,115,796,433
Total 8,413,597 $ 102.854 8,413,597 $ 3,115,796,433


Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 1, 2023 - July 31, 2023	—	(1)	$	—	—	$	1,709,092,863	(2)
August 1, 2023 - August 31, 2023	—	(1)	—		—	1,709,092,863		(2)
September 1, 2023 - September 30, 2023	—	(1)	—		—	1,709,092,863		(2)
Total	—	(1)	—		—	$	1,709,092,863	(2)

1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.

2830

Table of Contents

Item 6. Exhibits


Exhibit No.						Exhibit

~~3.1~~						~~By-Laws of Abbott Laboratories, as amended and restated effective September 15, 2022, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K fi~~l e ~~d on September 15, 2022~~.

31.1						Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2						Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1						Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2						Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101						The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, ~~2022,~~2023, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.

104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).

2931

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ABBOTT LABORATORIES

By:			/s/ ~~Robert E. Funck, Jr.~~PHILIP P. BOUDREAU
			~~Robert E. Funck, Jr.~~Philip P. Boudreau
			~~Executive~~Senior Vice President, Finance and Chief Financial Officer

			Date: November 1, ~~2022~~2023

3032


Part I - Financial Information
			Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings			3
Condensed Consolidated Statement of Comprehensive Income			4
Condensed Consolidated Balance Sheet			5
Condensed Consolidated Statement of Shareholders’ Investment			6
Condensed Consolidated Statement of Cash Flows			8
Notes to the Condensed Consolidated Financial Statements			9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			2224

Item 4. Controls and Procedures			2830

Part II - Other Information			2830

Item 1. Legal Proceedings			2830

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			2830

Item 6. Exhibits			2931

Signature			3032


(in millions)	Inventory- Related Charges		Fixed Asset Write-Downs		Other Exit Costs		Total
Restructuring charges recorded in 2021	$	248	$	80	$	113	$	441
Payments	—		—		(90)		(90)
Other non-cash	(248)		(80)		—		(328)
Accrued balance at December 31, 2021	—		—		23		23
Payments and other adjustments	—		—		(10)		(10)
Accrued balance at September 30, 2022	$	—	$	—	$	13	$	13